Replies to post #16055 on ScripsAmerica Inc. (SCRCQ)

[coolerheadsprevail]

Alleyba says.................

............that you are not taking into consideraton the other streams of revenue. i.e. China and Hong Kong. You also negelct to factor in that SCRC will be receiving licenses in 5 states to sell generic and controlled substance drugs so conservatively extrapolate those numbers 5X TN. Although I do not know if PIMD is done you forgot those revenues as well

If you go back to cwell’s OP as well as my reply, you should be able to see fairly clearly that the context of my numbers was STRICTLY based upon the revenue sources that cwell had identified and included in his $500k per month from specifically the NJ compounding pharmacy as well as $500k per month from Tenn Rx.

When the DEA license for controlled substances will be received is still murky as this has been like China in the sense that it seems to be an “any time now” scenario that keeps playing out month after month w/no change in status.

In addition, SCRC will need to hire additional sales reps to pursue leads in these new markets – and these leads take time to cultivate.

I don’t think any of us have any idea of how much or how little to value the impact of revenues (especially for a time period as short-term and rapidly approaching as Q2) for a market which SCRC has no historical baseline for – especially since SCRC still has no approval for these products in these markets yet and has no sales personnel to even pursue any such sales (albeit, I would expect SCRC to begin hiring them expeditiously upon receiving DEA approval).

To suggest that they will immediately contribute the amounts necessary in order for cwell's Q2 predictions to come true would be terrific -- but realistically, my opinion is that it is highly unlikely for Q2. You are free to form your own opinion.